{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Winkler C"],"funding":["Cancer Research UK","EC | European Regional Development Fund","Claudia Winkler is supported by an AstraZeneca PostDoc Fellowship funding.","Wellcome Trust"],"pagination":["951-962"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7921667"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["124(5)"],"pubmed_abstract":["<h4>Background</h4>Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive biomarker to DDA and/or DNA damage-response inhibitor (DDRi) therapies.<h4>Methods</h4>We used a multidisciplinary effort combining specific immunohistochemistry, pharmacology tests, anticancer combination therapies and mechanistic studies to assess SLFN11 as a potential biomarker for stratification of patients treated with several DDA and/or DDRi in the preclinical and clinical setting.<h4>Results</h4>SLFN11 protein associated with both preclinical and patient treatment response to DDA, but not"],"journal":["British journal of cancer"],"pubmed_title":["SLFN11 informs on standard of care and novel treatments in a wide range of cancer models."],"pmcid":["PMC7921667"],"funding_grant_id":["206194","FIS [PI17/01080]","Miguel Servet [CP14/00228]","Transcan-2 TH4RESPONS (AC15/00063)","22897"],"pubmed_authors":["Armenia J","Leo E","Coker EA","Tobalina L","Baird T","Winkler C","Wang AT","Jones GN","O'Connor MJ","Pierce AJ","Sale MJ","Lau A","Petreus T","Jaaks P","Serra V","Garnett MJ"],"additional_accession":[]},"is_claimable":false,"name":"SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.","description":"<h4>Background</h4>Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive biomarker to DDA and/or DNA damage-response inhibitor (DDRi) therapies.<h4>Methods</h4>We used a multidisciplinary effort combining specific immunohistochemistry, pharmacology tests, anticancer combination therapies and mechanistic studies to assess SLFN11 as a potential biomarker for stratification of patients treated with several DDA and/or DDRi in the preclinical and clinical setting.<h4>Results</h4>SLFN11 protein associated with both preclinical and patient treatment response to DDA, but not","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-07-16T01:56:45.094Z","creation":"2026-07-09T10:36:42.501Z"},"accession":"S-EPMC7921667","cross_references":{"pubmed":["33339894"],"doi":["10.1038/s41416-020-01199-4"]}}